Neurocrine Biosciences, Inc.
NBIX
$155.80
$5.213.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.12% | 1.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.12% | 1.33% | |||
| Cost of Revenue | 12.40% | 4.47% | |||
| Gross Profit | -4.76% | -0.23% | |||
| SG&A Expenses | 5.29% | 3.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.68% | 4.09% | |||
| Operating Income | -18.13% | -5.06% | |||
| Income Before Tax | 3.09% | -17.96% | |||
| Income Tax Expenses | -42.94% | 4.13% | |||
| Earnings from Continuing Operations | 28.76% | -26.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.76% | -26.63% | |||
| EBIT | -18.13% | -5.06% | |||
| EBITDA | -17.64% | -4.98% | |||
| EPS Basic | 27.99% | -27.00% | |||
| Normalized Basic EPS | -15.88% | -3.73% | |||
| EPS Diluted | 29.20% | -27.53% | |||
| Normalized Diluted EPS | -15.13% | -4.37% | |||
| Average Basic Shares Outstanding | 0.60% | 0.50% | |||
| Average Diluted Shares Outstanding | -0.29% | 1.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||